Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 13, 2003Journal of Clinical Oncology

Improved Outcomes From Adding Sequential Paclitaxel but Not From Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients With Node-Positive Primary Breast Cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

IHI. Craig HendersonNorthwell Health
Donald A. Berry
Donald A. BerryUniversité Claude Bernard Lyon 1
George D. Demetri
George D. DemetriUniversité Claude Bernard Lyon 1

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Henderson et al. (2003) studied this question.

synapsesocial.com/papers/6a0cb4dfe8a76b3043889b64https://doi.org/10.1200/jco.2003.02.063
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15.1990 · 625 citations
  2. 2Dose and Dose Intensity of Adjuvant Chemotherapy for Stage II, Node-Positive Breast Carcinoma1994 · 578 citations
  3. 3Reduction of Doxorubicin Cardiotoxicity by Prolonged Continuous Intravenous Infusion1982 · 768 citations
  4. 4THE IMPACT OF NATIONAL CANCER ACT1991 · 797 citations